Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2026)

Stoke Therapeutics' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 44.58% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 44.58% decrease from a year earlier, with the FY2025 full-year figure at $11.9 million, down 37.33% from the prior year.
• Current Deferred Revenue slipped to $10.1 million in Q1 2026 per STOK's latest filing, from $11.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $31.6 million in Q3 2024 and bottomed at $5.8 million in Q3 2025.
• The 5-year median for Current Deferred Revenue is $12.8 million (2022), against an average of $14.4 million.
• Across the five-year window, Current Deferred Revenue soared 261.9% in 2024 and tumbled 81.77% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $14.9 million in 2022, then advanced by 2.88% to $15.3 million in 2023, then advanced by 24.05% to $19.0 million in 2024, then tumbled by 37.33% to $11.9 million in 2025, then decreased by 15.42% to $10.1 million in 2026.
• Per Business Quant, the three latest STOK Current Deferred Revenue figures stand at $10.1 million (Q1 2026), $11.9 million (Q4 2025), and $5.8 million (Q3 2025).